InnoCare Advances Phase III Orelabrutinib Trial for SLE
BEIJING, April 29, 2026 InnoCare Pharma has announced that the first patient has been dosed in the registrational Phase...
phase III trial
Advertisement
Vanda Pharma Publishes Phase III Imsidolimab Data
WASHINGTON, April 28, 2026 Vanda Pharmaceuticals Inc. has announced the publication of pivotal Phase III clinical data evaluating imsidolimab,...
Boehringer Survodutide Shows 16.6% Weight Loss in Phase III
INGELHEIM, GERMANY, April 28, 2026 Boehringer Ingelheim has announced positive Phase III results for its investigational dual agonist survodutide,...
AstraZeneca Saphnelo Pen Gains FDA Approval in US
CAMBRIDGE, UK, April 27, 2026 AstraZeneca has received U.S. Food and Drug Administration (FDA) approval for the subcutaneous self-administration...
DualityBio Advances HER2 ADC Toward China Approval
SHANGHAI, China, April 9, 2026 DualityBio has announced that the China National Medical Products Administration (NMPA) has accepted the...
Advertisements
GSK Wins China Approval for Exdensur in Severe Asthma
LONDON, UK — March 30, 2026 In a major advancement in respiratory medicine and biologic drug innovation, GSK plc...
GSK Bepirovirsen Wins EMA Review for Hepatitis B Drug
London, UK | March 27, 2026 EMA Accepts First-in-Class Hepatitis B Therapy for Review GSK has announced that the...
Pharming Group Secures Japan Approval for Joenja in APDS
LEIDEN, NETHERLANDS, March 24, 2026 Pharming Group has announced that Japan’s Ministry of Health, Labour and Welfare has approved...
FDA Approves Rhythm Pharmaceuticals’ IMCIVREE for Acquired Hypothalamic Obesity
BOSTON, March 19, 2026 Rhythm Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Imcivree (setmelanotide) for...
Iza-bren Meets Dual Endpoints in Phase III TNBC
REDMOND, Wash. & PRINCETON, N.J., February 26, 2026 SystImmune, Inc. and Bristol Myers Squibb announced positive interim topline results...
Advertisement
